BR112017003162A2 - método de peguilação - Google Patents

método de peguilação

Info

Publication number
BR112017003162A2
BR112017003162A2 BR112017003162A BR112017003162A BR112017003162A2 BR 112017003162 A2 BR112017003162 A2 BR 112017003162A2 BR 112017003162 A BR112017003162 A BR 112017003162A BR 112017003162 A BR112017003162 A BR 112017003162A BR 112017003162 A2 BR112017003162 A2 BR 112017003162A2
Authority
BR
Brazil
Prior art keywords
pegylation method
pegylation
pegylating
relates
present
Prior art date
Application number
BR112017003162A
Other languages
English (en)
Inventor
Jaquez Orlando
S Gronke Robert
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of BR112017003162A2 publication Critical patent/BR112017003162A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

a presente invenção refere-se a um método para peguilação do beta interferon.
BR112017003162A 2014-08-19 2015-08-18 método de peguilação BR112017003162A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461997000P 2014-08-19 2014-08-19
PCT/US2015/045678 WO2017030563A1 (en) 2014-08-19 2015-08-18 Pegylation method

Publications (1)

Publication Number Publication Date
BR112017003162A2 true BR112017003162A2 (pt) 2017-11-28

Family

ID=59559468

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003162A BR112017003162A2 (pt) 2014-08-19 2015-08-18 método de peguilação

Country Status (13)

Country Link
US (1) US11318207B2 (pt)
EP (2) EP3782652A1 (pt)
BR (1) BR112017003162A2 (pt)
CO (1) CO2017002512A2 (pt)
CY (1) CY1123685T1 (pt)
DK (1) DK3183264T3 (pt)
ES (1) ES2824028T3 (pt)
HR (1) HRP20201725T1 (pt)
LT (1) LT3183264T (pt)
MX (1) MX2017002140A (pt)
RS (1) RS61128B1 (pt)
SI (1) SI3183264T1 (pt)
WO (1) WO2017030563A1 (pt)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
DE3262575D1 (en) 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
PT1075281E (pt) 1998-04-28 2004-11-30 Applied Research Systems Conjugados poliol-ifn-beta
TWI266801B (en) 1999-07-26 2006-11-21 Applied Research Systems Polyol-IFN-beta conjugates
HUE028163T2 (en) * 2002-01-18 2016-11-28 Biogen Ma Inc Polyalkylene polymer compounds and their use
EP1545623B1 (en) * 2002-09-27 2007-05-09 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol)
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
CU23556A1 (es) 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
GB0908393D0 (en) 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
US20120258926A1 (en) * 2009-12-15 2012-10-11 Valentyn Antochshuk Formulations of acadesine
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
CN102453089B (zh) 2010-10-25 2014-06-04 北京凯因科技股份有限公司 重组集成干扰素变异体聚乙二醇偶联物的制备和应用
WO2014130811A1 (en) * 2013-02-22 2014-08-28 Biogen Idec Ma Inc Interferon beta formulation
CN103113466B (zh) 2013-03-01 2015-06-03 中国科学院过程工程研究所 聚乙二醇修饰的重组人干扰素β-1b及制备方法
CN103936847B (zh) 2013-12-24 2014-12-10 北京凯因科技股份有限公司 Peg-sa及其药物组合物

Also Published As

Publication number Publication date
DK3183264T3 (da) 2020-11-02
LT3183264T (lt) 2021-01-11
WO2017030563A8 (en) 2017-03-16
RS61128B1 (sr) 2020-12-31
HRP20201725T1 (hr) 2021-03-05
EP3782652A1 (en) 2021-02-24
CO2017002512A2 (es) 2017-05-31
US11318207B2 (en) 2022-05-03
WO2017030563A1 (en) 2017-02-23
US20170232111A1 (en) 2017-08-17
EP3183264B1 (en) 2020-07-29
SI3183264T1 (sl) 2021-03-31
CY1123685T1 (el) 2022-03-24
EP3183264A1 (en) 2017-06-28
ES2824028T3 (es) 2021-05-11
MX2017002140A (es) 2017-08-21

Similar Documents

Publication Publication Date Title
GB2540015B (en) Intermediate linear positioning
DK3233882T3 (da) Fluorinerede cykliske dinukleotider til cytokininduktion
PL3157458T3 (pl) Nakładki korekcyjne z elastycznymi warstwami
DK3536380T3 (da) Hurtigtvirkende insulinsammensætninger
DK3233108T3 (da) Hurtigtvirkende insulinsammensætninger
EP3307158A4 (en) BOLUS FOR VEAL
BR112017000446A2 (pt) arranjos de estação de acionamento
MA51576A (fr) Polythérapie
DK3294287T3 (da) Oxabicycloheptan-prodrugs
EP3623755C0 (en) RULE
EP3356600A4 (en) PNEUMATIC BALLAST BLOWER FOR RAILWAY APPLICATIONS
GB201504848D0 (en) Linear recessed structure for lighting
MA44385A (fr) Pince
GB201518570D0 (en) Blade positioning
SG11201610326VA (en) Orthodontic aligners
HK1253094A1 (zh) 多肽組合物
BR112017003162A2 (pt) método de peguilação
MX2021012843A (es) Metodo de pegilacion.
ES1149633Y (es) Mesa de centro
DK3119380T3 (da) Sammensætning omfattende biprodukter
ES1135500Y (es) Mesa para efectos de ilusionismo
AU366960S (en) Chalkboard
MA42965A (fr) Polythérapie
GB201505315D0 (en) Positioning arrangement
GB2532071B (en) Slide Rail Assembly

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/08/2015, OBSERVADAS AS CONDICOES LEGAIS